Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
6.27
+0.19 (3.13%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.95 - 6.28
52 week 4.41 - 9.83
Open 6.06
Vol / Avg. 2.31M/3.25M
Mkt cap 920.27M
P/E     -
Div/yield     -
EPS -1.42
Shares 142.33M
Beta 1.55
Inst. own 112%
Feb 24, 2017
Q4 2016 Amicus Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 10, 2017
Amicus Therapeutics Inc at JPMorgan Healthcare Conference - Q&A session
Jan 10, 2017
Amicus Therapeutics Inc at JPMorgan Healthcare Conference
Dec 8, 2016
Amicus Therapeutics Inc Preliminary Phase 1/2 Pompe Data Conference Call
Nov 28, 2016
Amicus Therapeutics Inc Migalastat U.S. Regulatory Update - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -2193.42% -
Operating margin -2112.84% -
EBITD margin - -
Return on average assets -20.43% -23.63%
Return on average equity -55.79% -56.22%
Employees 185 -
CDP Score - -

Address

1 Cedarbrook Dr
CRANBURY, NJ 08512-3618
United States - Map
+1-609-6622000 (Phone)
+1-609-6622001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Daphne E. Quimi Senior Vice President - Finance and Administration, Corporate Controller
Age: 50
Bio & Compensation  - Reuters
Kurt J. Andrews Senior Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
David Allsop Senior Vice President - International
Bio & Compensation  - Reuters
Hung Viet Do Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Andrew E. Mulberg M.D. Vice President - Regulatory Strategy
Bio & Compensation  - Reuters
Ellen Rosenberg General Counsel and Corporate Secretary
Bio & Compensation  - Reuters
Jay A. Barth M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters